CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Home Spirometry — Coverage Criteria

Policy on coverage and medical necessity of home spirometry devices for pulmonary function monitoring, including use in lung transplant recipients; applies to Blue Cross & Blue Shield of Rhode Island products (Commercial and BlueCHiP for Medicare).

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHome Spirometry — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify member-specific benefits and eligibility in the member's subscriber or employer agreement before providing services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredBlueCHiP for Medicare coverage stance

Not medically necessaryCommercial products coverage stance

codes specifiedCPT coding notes

Lung transplantPrimary clinical focus

Coverage Determination and Rationale

Overall coverage determination

Covered when ALL of the following are met:

Policy conclusion: Home spirometry is not covered for BlueCHiP for Medicare and is considered not medically necessary for Commercial Products because the evidence is insufficient to determine the effects of the technology on health outcomes.

Primary evidence base relates to lung transplant recipients; studies are limited and do not demonstrate improved net health outcomes.

For BlueCHiP for Medicare, home spirometry is not covered. For Commercial products, home spirometry is considered not medically necessary. These determinations reflect the policy conclusion that the current evidence is insufficient to establish that home spirometry improves health outcomes, and therefore coverage is not supported under the BlueCHiP for Medicare program and the service is not medically necessary for Commercial members.

The commercial not medically necessary determination is based on limited and low-quality evidence. Studies of home spirometry are few, primarily involve lung transplant recipients, and most do not evaluate effects on meaningful health outcomes. Because available data do not demonstrate that routine home spirometry leads to improved net health outcomes (for example, reductions in rejection-related morbidity, hospitalizations, or mortality), the technology is not supported for routine clinical use in Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyHome Spirometry — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionVerify member-specific benefits and eligibility in the member's subscriber or employer agreement before providing services.

SourceLink

On This Page

Provider Requirements, Prior Authorization, and Denials

Prior Authorization

Not applicable

Note

Member Eligibility and Benefit Verification

Benefits and eligibility are determined by the member's subscriber agreement/certificate and/or the employer agreement and will supersede this medical policy. Verify member-specific benefits and eligibility prior to providing services by contacting the provider call center or checking the member's plan documents. If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member unless the member was informed and agreed in writing in advance to pay at their own expense. This policy is for informational purposes and is not a guarantee of payment.

Denial Risk

Denial Triggers and Not Medically Necessary Conditions

BlueCHiP for Medicare: Home spirometry is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes. Commercial Products: Home spirometry is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes. The following CPT codes are either not covered for BlueCHiP for Medicare and/or considered not medically necessary for Commercial Products: 94014, 94015, 94016. Providers should bill and document accordingly; services subject to these determinations may be denied.

94014
94015
94016

Clinical Context

Home spirometry refers to battery-operated spirometers used by patients at home to obtain regular measurements of pulmonary function, typically forced expiratory volume in 1 second (FEV-1) and forced vital capacity (FVC). The primary clinical population studied for this technology has been lung transplant recipients, where daily home measurements have been proposed to identify presymptomatic changes that could indicate infection or rejection and prompt diagnostic evaluation such as transbronchial biopsy. Existing studies are few and most do not assess whether home spirometry improves patient-centered health outcomes.

Key Definitions

Definition — Home spirometry

TermHome spirometry (ambulatory spirometry)

DefinitionBattery-operated spirometers permitting regular daily measurement of pulmonary function in the home, typically forced expiratory volume in 1 second (FEV-1) and forced vital capacity (FVC).

Primary useRemote daily monitoring of pulmonary function, primarily investigated among lung transplant recipients to identify early infection or rejection.

Alternate nameAmbulatory spirometry

Evidence summaryFew studies; available literature generally did not evaluate effects on health outcomes and evidence is insufficient to demonstrate improved net health outcome.

Definition — Transbronchial biopsy

TermTransbronchial biopsy

DefinitionAn objective procedure used to distinguish rejection from infection in lung transplant recipients.

Typical schedulePerformed on a routine schedule post-transplant with additional biopsies if the patient becomes symptomatic.

Role in monitoringConsidered the only objective method to distinguish rejection versus infectious complications; may be prompted by abnormal home spirometry measurements.

Clinical contextUsed alongside other monitoring techniques (pulmonary function tests, serial chest x-rays, bronchoalveolar lavage) in the immediate post-operative period.

OpenPayer

Home Spirometry — Coverage Criteria

Coverage Determination and Rationale

Billing Codes and Status

Provider Requirements, Prior Authorization, and Denials

Clinical Context

Key Definitions

94015	Patient-initiated spirometric recording per 30-day period of time; recording (includes hook-up, reinforced education, data transmission, data capture, trend analysis, and periodic recalibration)
94016	Patient-initiated spirometric recording per 30-day of time; physician review and interpretation only period